Drug intelligence / Profile preview

NEX-20A

Development stage: Phase 1
Lead developer: Nanexa
Modality: Small Molecules
Administration: Subcutaneous

Overview

NEX-20A is a long-acting formulation of lenalidomide, based on the PharmaShell system, intended for the maintenance treatment of multiple myeloma. It is administered as a subcutaneous prolonged-release injection, designed to provide controlled release of the drug for up to 21 days. Pharmacokinetic data from Phase 1 studies confirmed a release profile with a low initial release on the first day, which helps maintain plasma levels over the entire treatment period.

Other names: Lenalidomide prolonged-release formulationLong-acting lenalidomidePharmaShell lenalidomide

Targets

CRBN (Cereblon)

Beyond the preview

Go deeper on NEX-20A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEX-20A.

Explore the full profile